Insulin LisproHumalog U200
Recommended EndocrinologyUnrestrictedNot applicable line 💬 consumer voice
Treatment of type 1 and type 2 diabetes mellitus in patients who require higher daily insulin doses of >20 U.
1
Submissions
2017–17
On the record
—
ICER range
Cost-min
Cost basis
Decisions on record
- Meeting Nov 2017 Recommended Diabetes mellitus
- Meeting Mar 2009 Recommended Anti-diabetic agent no PSD
Access path
- TGA registered · Humalog U200
TGA label narrower than the PBS population
- Nov 2017Recommended
vs insulin lispro 100 units/mL (Humalog U100)
- PBS listing · Unrestricted
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
7.1 The PBAC recommended the listing of the new strength of insulin lispro Humalog U200 for the treatment of type 1 and 2 diabetes mellitus. Listing was recommended on a cost minimisation basis per unit of insulin with insulin lispro Humalog U100, noting that a price reduction may be appropriate to achieve a listing that is cost- neutral to Government in the context of an increased potential for wastage resulting from the higher amount of drug provided …PSD · Nov 2017
7.2 The PBAC considered that the listing of Humalog U200 may meet a small clinical need for patients who require high daily doses of insulin lispro. 5PSD · Nov 2017
Economic analysis
6.5 As a minor submission, there was no economic comparison presented/ an economic comparison was not relevant.PSD · Nov 2017
6.6 While not stated in the explicitly in the submission the price requested for Humalog 200 U/mL equated to a cost minimisation at a cost per unit insulin basis with an incorrect adjustment for a statutory 16% price reduction.PSD · Nov 2017
Cost-effectiveness
Cost-minimisation analysis on a per-unit insulin basis; no ICER calculated as this was a minor submission (formulation/strength change).
Price cut / RSA neededCost-effectiveness accepted
Decision context
PopulationPatients with type 1 and type 2 diabetes mellitus who require insulin for maintenance of normal glucose homeostasis, specifically those requiring higher daily insulin doses of >20 U.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2017 | Recommended | insulin lispro 100 units/mL (Humalog U100) | — | Single-arm · Surrogate |
Consumer voice
No consumer comments were received for this item.
The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients requiring higher daily insulin doses >20 U, a subset of all TGA-labeled insulin-requiring patients.